Elitra: Filling the antimicrobial pool
One problem in treating fungal and bacterial infections is that existing antibiotics act against a relatively limited set of targets. This limited set of products with similar mechanisms of action gives rise to rapid and extensive microbial drug resistance. Elitra Pharmaceuticals Inc. hopes to address the problem by increasing both the number of antimicrobial targets and therapeutics.
The company is developing a relational database of essential genes and